Whats happening to the biosimilars division????

Discussion in 'Pfizer' started by anonymous, May 13, 2019 at 9:50 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Until Pfizer can make it a generic pricing model, it needs to be spun off to CSF or co promote
     

  2. anonymous

    anonymous Guest

    weakest in all of Pfizer? Ok I’ll take the bait. I’m guessing this comes from a sub specialty at best if not primary care rep at Pfizer. Love to break it to you. The biosim reps likely have the most sought after skill set in the industry. We don’t do the SP or go pick up at cvs model. We call on actual financial decision makers and have access you would dream of in hospitals. I would gladly interview side by side the best oncology rep in Pfizer. Odds are my skill set wins out. Good try.
     
  3. anonymous

    anonymous Guest

    And there are many more biosims coming to market.
     
  4. anonymous

    anonymous Guest

    Selling on price alone isn’t selling. Access to financial/purchasing people makes you no different than the guy selling toilet paper. Your skill set is selling generics.... if you want to call it skill. In the “Cheapest is Best” arena, anyone with a decent product with a competitive price can do well. You may think you’re superior, but you really don’t reach the level of equal.
    But, hey, nothing wrong with your bravado and ego, as long as you believe it.
     
  5. anonymous

    anonymous Guest

    Hahahahaha! PFE can just send bids via email, you completely unneeded....just useless overhead, and your days are numbered.
     
  6. anonymous

    anonymous Guest

    After 4 yrs it is obvious the team they hired to sell it can not sell.
    So Richard wants to give BioSimilars to Xeljanz field force to have products post LOE.
    Heard its in the 2022 strategic planning.
     
  7. anonymous

    anonymous Guest

    The company figured if they show up and throw up all will be well. I’m sure the reps were not well prepared, but PFE totally miscalculated and mismanaged; probably relied on consultants and there is no successful historical precedent to draw from. This portfolio needs to be out-licensed to a small nimble company that is willing to take risks vs a bureaucratic OIG paranoid lawyer run shit show.
     
  8. anonymous

    anonymous Guest

    Everything in this is exactly why you are inept. Selling a generic? It’s not a generic. It’s a Biosimilar and if you had any knowledge of biologics you would know the rationale. Do I have an ego or am I speaking the truth about the skill set and the level this division is in versus the pull pushers?
     
  9. anonymous

    anonymous Guest

     
  10. anonymous

    anonymous Guest

    It is a contract job and always will be.
     
  11. anonymous

    anonymous Guest

    No different than meeting with a toilet paper sales person? That’s funny. That is the difference between selling a drug paid through pharmacy benefit as opposed to major medical. A financial person is involved as a practice or hospital is shelling out all the $$. Again, different set of skills. Totally different business model.
     
  12. anonymous

    anonymous Guest

    It’s all semantics. The Govt and the FDA had to keep it out of generic companies’ hands so kept the biosim name vs. generic. In truth that’s what it is.
    You keep telling yourself what makes you happy and feeds you’re overblown ego.
    BTW, I was with Hospira and was slated to join the biosim division but declined. I knew H and P would turn it into a shitshow, and I was right.
     
  13. anonymous

    anonymous Guest

     
  14. anonymous

    anonymous Guest

    They’re both commodities and sell on price. Same skill set.... out of the product catalog.
     
  15. anonymous

    anonymous Guest

    Evidently you aren’t a very good sales person because the division is on the auction block. Your management was a feckless bunch of ego driven fools who couldn’t get out of their own way.
     
  16. anonymous

    anonymous Guest

     
  17. anonymous

    anonymous Guest

    I’m very curious as to why biosims haven’t been able to get more traction. I get it PFE has not (they would fuck up a wet dream) but overall no company has
     
  18. anonymous

    anonymous Guest

    Love this: I am currently interviewing for a Biosimilars TPS position @ Sandoz and I think I have the best skill set in the industry calling on the key decision makers/power players at all local IDNs. I have access reps would dream to have. Takes years to get there; but I agree with the above poster that this is the greatest skill set in the industry.
     
  19. anonymous

    anonymous Guest

    Exactly!
     
  20. anonymous

    anonymous Guest

    Hahahahaha! You two clowns drink too much kool-aid. Any fool can sell generics.
    You could pull a bum off the street, Give him the data that shows equivalency, the price differentiation, and he has the same skill set you both have.
    But whatever floats your boat is all that counts. Keep rowing because your boat is taking on water.....fast.